Physician profile
Alan Arthur
NPI 1780811521
$432.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $140 · 2021: $99.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $70.96 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $52.50 | 2019 | |
| Sunovion Pharmaceuticals INC. | $46.15 | 2019 | |
| Neurocrine Biosciences, INC. | $46.12 | 2019-2020 | |
| Novo Nordisk INC | $35.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $33.40 | 2019-2020 | |
| Pfizer INC. | $26.94 | 2020 | |
| Merck Sharp & Dohme LLC | $26.75 | 2020-2021 | |
| Glaxosmithkline, LLC. | $23.23 | 2021 | |
| Alkermes, INC. | $22.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.87 | 2019 | |
| Sanofi Pasteur INC. | $12.67 | 2019 | |
| Indivior INC. | $12.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.27 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.